Novo Nordisk

Why Novo Nordisk stock was melting on Monday The Motley Fool20:50
Novo Nordisk gears up for December Ozempic launch in India, sources say Yahoo! US18:11
Novo Nordisk's latest clinical result is sending the stock plunging. Here's what investors need to know. The Motley Fool12:45
Fat profits ahead: Ozempic patent due to expire, Indian pharma lines up for generics gold rush The Telegraph, Calcutta05:48
NVO stock up as amycretin shows strong weight loss in Type 2 diabetes Zacks16:49
Medicare negotiations 2.0 Slash prices up to 85%, but mean cuts barely budge Scrip Pharma Intelligence11:00
Ozempic 2.0? What we know about future of weight loss pills The Fresno Bee16:55

Latest News

In the last 15 minutes

Delhi High Court bars Sun Pharma from selling its semaglutide drug in India until Novo's patent … Mint07:27

In the last half-hour

Delhi HC allows Sun Pharma to manufacture, export its weight loss drug The Business Standard07:25

In the last hour

Delhi HC allows Sun Pharma to manufacture, export its own weight loss drug The Economic Times06:47

Yesterday

National Advertising Division Puts Compounded GLP-1 Advertising on a Diet National Law Review21:30 9-Dec-25

Will Pfizer’s YaoPharma deal deliver a powerful new oral obesity pill? Invezz20:52 9-Dec-25

Novo Nordisk moves HC to stop Sun Pharma from launching weight loss drug The Business Standard15:43 9-Dec-25

Novo Nordisk has completed its acquisition of Akero Therapeutics Novo Nordisk14:11 9-Dec-25

Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease PMLiVE13:18 9-Dec-25

Novo Nordisk moves Delhi HC to block Sun Pharma’s semaglutide launch Mint06:53 9-Dec-25

In the last 7 days

Chancery Blocks Opt-Out In $32M Emisphere Settlement Law36023:38 8-Dec-25

Why Novo Nordisk Stock Was Melting on Monday The Motley Fool20:50 8-Dec-25

Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatment The Economic Times03:07 8-Dec-25

What's Going On With Hims & Hers Stock Wednesday? Benzinga05:08 7-Dec-25

This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? The Motley Fool16:23 5-Dec-25

Healthify seeks more weight-loss drug partnerships after Novo Nordisk deal The Business Standard11:59 5-Dec-25

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi Zacks11:51 5-Dec-25

Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact The Hindu Business Line10:24 5-Dec-25

India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact Yahoo! US10:07 5-Dec-25

Dr Reddy’s welcomes favourable court ruling on Semaglutide in dispute with Novo Nordisk The Hindu Business Line03:15 5-Dec-25

3 Large Drug Stocks to Watch as the Industry Shows Some Recovery Zacks15:39 4-Dec-25

New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of… PR Newswire (Press Release)15:04 4-Dec-25

‘Stone cold negative’: Failed studies sink hopes for Novo Nordisk’s GLP-1 in Alzheimer’s care Malay Mail13:00 4-Dec-25

Denmark raises growth outlook despite Novo Nordisk woes Investing.com12:13 4-Dec-25

Novo Nordisk races to India Ozempic launch after interim injunction denied IAM11:39 4-Dec-25

Novo Nordisk can acquire Akero Bundeskartellamt09:36 4-Dec-25

Healthify, Novo Nordisk India Launch AI-Enabled Patient Support Program for Obesity Care Analytics India Magazine09:29 4-Dec-25

Dr Reddy’s gets Delhi HC’s permission to export generics of Novo Nordisk’s semaglutide drug The Hindu Business Line08:52 4-Dec-25

Novo Nordisk gears up for December Ozempic launch in India The Hindu Business Line05:08 4-Dec-25

Novo Not Ready to Quit Alzheimer’s Amid Ozempic Pill Setback (1) Bloomberg Law04:54 4-Dec-25

Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment The Times of India03:38 4-Dec-25

Novo Nordisk to launch diabetes drug Ozempic in India in December The Telegraph, Calcutta02:01 4-Dec-25

Novo Nordisk gears up for December Ozempic launch in India, sources say Yahoo! US18:11 3-Dec-25

Akero Therapeutics Shareholders Approve Novo Nordisk Merger TipRanks15:59 3-Dec-25

Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market? Zacks15:31 3-Dec-25

Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock? The Motley Fool15:04 3-Dec-25

Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks Global News14:51 3-Dec-25

Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors PR Newswire (Press Release)13:31 3-Dec-25

India weight-loss market reset? In setback for Novo Nordisk, Dr Reddy's Lab allowed to make… The Times of India11:10 3-Dec-25

Novo Nordisk India partners with Healthify to launch AI-enabled patient support programme The Times of India09:49 3-Dec-25

Dr Reddy’s Gets Nod to Export Weight-Loss Drug, Domestic Launch Barred Till March 2026 Outlook Business07:47 3-Dec-25

Dr Reddy’s can make Novo’s weight loss drug, rules HC The Times of India02:01 3-Dec-25

In the last month

New findings on weight-loss drugs and Alzheimer’s ScienceNorway23:06 2-Dec-25

HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26 The Economic Times19:43 2-Dec-25

GLP-1 Drugs for Cats? High-Dose Wegovy Heads to FDA; Smartphone-Obesity Link in Kids Medpage Today19:20 2-Dec-25

Why GLP-1s Won’t Be Prescribed for Alzheimer’s Soon Oprah Daily18:15 2-Dec-25

Dr Reddy’s wins Delhi HC nod to export semaglutide to non-patent markets Mint17:02 2-Dec-25

Novo Nordisk to test next-gen obesity drug CagriSema in children BNN Bloomberg16:06 2-Dec-25

Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock Zacks15:03 2-Dec-25

Is Novo Nordisk a Hidden Opportunity After Its 9.6% Weekly Gain? Simply Wall St02:22 2-Dec-25

AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock? Zacks17:06 1-Dec-25

Eli Lilly cuts price of Zepbound in heightened weight-loss drug competition Proactive Investors (US)16:25 1-Dec-25

Eli Lilly cuts cost of Zepbound vials in weight loss drug price war's latest salvo Quartz15:15 1-Dec-25

Eli Lilly slashes obesity drug price by up to 20% Los Angeles Times15:09 1-Dec-25

Eli Lilly Lowers Weight-Loss Drug Zepbound Prices After Trump Deal Forbes14:45 1-Dec-25

Omeros Completes Major Asset Deal with Novo Nordisk TipRanks14:03 1-Dec-25

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk… Business Wire (Press Release)13:31 1-Dec-25

Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know. The Motley Fool12:45 1-Dec-25

'There's never been a drug with this range': The weight loss boom is just getting started Quartz10:10 1-Dec-25

Novo Nordisk’s valuation at risk as competition rises, PT trimmed: Jefferies Investing.com06:33 1-Dec-25

Fat profits ahead: Ozempic patent due to expire, Indian pharma lines up for generics gold rush The Telegraph, Calcutta05:48 1-Dec-25

The Ozempic effect reshaping supermarkets and stock markets ABC Online18:05 30-Nov-25

Why Novo Nordisk Stock Just Hit a 4-Year Low The Motley Fool01:06 30-Nov-25

Novo Nordisk’s Stock Surges Amid Drug Breakthrough TipRanks14:10 29-Nov-25

Novo Nordisk Stock Investors Get Huge News on Drug Trial Results The Motley Fool17:02 28-Nov-25

Ozempic 2.0? What We Know About Future of Weight Loss Pills The Fresno Bee16:55 28-Nov-25

Trump’s Ozempic Deal Will Supersede Medicare-Negotiated Price Bloomberg Law16:33 28-Nov-25

What is Ozempic 2.0? Will it be a gamechanger for weight loss? Here's all you need to know Mint13:15 28-Nov-25

How to Investigate Pharmaceutical Oligopolies Global Investigative Journalism Network08:05 28-Nov-25

Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet? Zacks17:56 27-Nov-25

Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy Zacks17:25 27-Nov-25

Novo Nordisk seeks fast FDA approval of higher-dose Wegovy Longevity Technology16:15 27-Nov-25

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 The Motley Fool13:40 27-Nov-25

Generic drugmakers to slash price plans as Novo cuts Wegovy rates The Business Standard09:23 27-Nov-25

Ozempic, Wegovy Medicare Prices Muddled by Trump’s Dueling Deals Bloomberg Law21:14 26-Nov-25

How Medicare’s new drug prices could reshape Novo Nordisk and european pharma Invezz20:31 26-Nov-25

Why Novo Nordisk Stock Is Moving Higher Today The Motley Fool20:24 26-Nov-25

Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy Benzinga18:37 26-Nov-25

Generic drug companies rework pricing to gain weight in India’s GLP-1 market as Novo Nordisk slashes Wegovy prices The Economic Times18:33 26-Nov-25

Novo Nordisk backs biotech start-up targeting aging Longevity Technology17:24 26-Nov-25

NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes Zacks16:49 26-Nov-25

Novo Nordisk spends priority voucher on Wegovy filing pharmaphorum14:27 26-Nov-25

Price cut for obesity drugs, HP job cuts, Tesla's robotaxi expansion Yahoo! US13:50 26-Nov-25

Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg PR Newswire (Press Release)13:00 26-Nov-25

Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes Clinical Trials Arena11:58 26-Nov-25

Medicare Negotiations 2.0 Slash Prices Up To 85%, But Mean Cuts Barely Budge Scrip Pharma Intelligence11:00 26-Nov-25

Did Pfizer Just Say "Checkmate" to Novo Nordisk? The Motley Fool10:03 26-Nov-25

Novo Nordisk’s Ozempic and Wegovy Prices Cut 71% under Medicare Plan TipRanks09:12 26-Nov-25

Team Novo Nordisk confirms ten rider Development Team for 2026 PR Newswire (Press Release)08:00 26-Nov-25

Medicare announces discounts on 15 drugs, including Ozempic and Wegovy London South East06:00 26-Nov-25

Medicare Negotiates 71% Discount on Novo’s Ozempic, Wegovy Bloomberg Law23:41 25-Nov-25

Amycretin Heads For Phase III In Type 2 Diabetes Scrip Pharma Intelligence23:07 25-Nov-25

Should You Buy the Massive Dip in Novo Nordisk Stock? Barchart21:14 25-Nov-25

Why Novo Nordisk Stock Keeps Getting Punished For Headlines That Don't Matter Benzinga19:42 25-Nov-25

Here's Why Novo Nordisk Stock Popped Today The Motley Fool19:18 25-Nov-25

Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer’s prevention Times LIVE18:56 25-Nov-25

Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says Benzinga18:30 25-Nov-25

NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies Zacks17:12 25-Nov-25

Novo Nordisk advances amycretin to late-stage trial after positive diabetes weight-loss results Jerusalem Post16:47 25-Nov-25

Alzheimer’s Phase III miss signals GLP-1RA combination therapy potential European Pharmaceutical Review15:37 25-Nov-25

Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients Benzinga15:27 25-Nov-25

Novo Nordisk’s Alzheimer’s GLP-1 gamble fails Longevity Technology15:21 25-Nov-25

Data sets up phase 3 trials for Novo's amycretin in diabetes pharmaphorum14:14 25-Nov-25

Novo Nordisk Reports Positive Phase 2 Results for Amycretin in Type 2 Diabetes TipRanks13:50 25-Nov-25

Novo Nordisk Stock (NVO) Rises as Amycretin Drug Shows Significant Weight Loss TipRanks13:30 25-Nov-25

Forbes Daily: Google’s AI Winning Streak Continues Amid Stunning Rebound Forbes13:23 25-Nov-25

Novo’s next-gen obesity drug shows positive results, heads to late-stage testing BNN Bloomberg13:22 25-Nov-25

Two Alzheimer’s Trial Failures Reveal Clinical Challenges Forbes13:09 25-Nov-25

Alzheimer's Association comments on failed Novo Nordisk GLP-1 trial Manufacturing Chemist12:20 25-Nov-25

5 things to know about the new obesity pills that are on the way NPR12:06 25-Nov-25

Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study The Times of India11:52 25-Nov-25

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes Novo Nordisk11:37 25-Nov-25

Novo Alzheimer’s drug trial failure a "missed opportunity" - Kepler Cheuvreux Investing.com10:21 25-Nov-25

Trending: Alphabet, Broadcom, Zoom, Novo Nordisk, EasyJet Yahoo! UK & Ireland09:32 25-Nov-25

Novo Nordisk: Alzheimer's Failure Puts More Pressure on Oral Semaglutide Launch in Obesity Morningstar09:19 25-Nov-25

Here’s why the Novo Nordisk stock has crashed by 70% Invezz09:02 25-Nov-25

view more headlines

10 Dec 07:27

About our Novo Nordisk news

Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our NewsNow feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.

Novo Nordisk

Latest News

About our Novo Nordisk news

Pharmaceuticals Top Stories

UK Top Stories

World Top Stories